Skip to content

Amgen

A multinational biotechnology company developing, manufacturing, and commercializing medicines for serious and difficult-to-treat diseases.

Last updated November 16, 2026

AI crawler reads

180requests

8AI
  • OpenAI115
  • Perplexity21
  • Amazon16
  • Shape13
  • Anthropic6
  • +39
Profile
128
Controversies
20
JSON · MD
0
First read
Oct 29, 2026
Latest read
Nov 17, 2026

From this site's server log

Overview

Amgen is a United States-based multinational biotechnology company headquartered in Thousand Oaks, California. Its name is derived from Applied Molecular Genetics, the company’s original corporate name. Founded in 1980, Amgen became one of the foundational companies of modern biotechnology by applying recombinant-DNA science, molecular biology, human genetics, and large-scale biomanufacturing to the development of medicines. Its therapeutic focus includes oncology, hematology, inflammation, bone health, cardiovascular disease, nephrology, respiratory disease, rare disorders, and metabolic conditions. The company began as Applied Molecular Genetics and initially investigated several uses of genetic engineering, including recombinant proteins and insulin. In 1983 it completed an initial public offering and adopted the Amgen name. During the same period, a research team led by Fu-Kuen Lin cloned the human erythropoietin gene. That work produced Epogen, approved in the United States in 1989, which helped establish the commercial viability of biotechnology-derived medicines. Subsequent products such as Neupogen and Neulasta expanded Amgen’s role in supportive cancer care, while Enbrel created a major franchise in autoimmune disease. Aranesp extended its expertise in erythropoiesis. Amgen later built substantial positions in bone disease and oncology through denosumab products Prolia and XGEVA, the osteoporosis therapy Evenity, the multiple-myeloma medicine Kyprolis, and the bispecific T-cell engager Blincyto. Repatha brought a biologic approach to LDL-cholesterol reduction, and Otezla expanded the company’s immunology portfolio with an oral small-molecule product. Additional products include Nplate, Vectibix, Tezspire, Aimovig, biosimilars, and the KRAS G12C inhibitor Lumakras. The company combines internal research with licensing, partnerships, and acquisitions. Important transactions have included the purchases of deCODE Genetics, Micromet, Five Prime Therapeutics, Rodeo Therapeutics, ChemoCentryx, and Horizon Therapeutics. Horizon, acquired in 2023, strengthened Amgen’s rare-disease business through products including Tepezza and Krystexxa. Amgen also collaborates with companies such as AstraZeneca, Kyowa Kirin, Generate Biomedicines, Plexium, and Amazon Web Services. Amgen operates research, manufacturing, and commercial organizations across multiple regions. Its manufacturing network includes sites in Puerto Rico, Ireland, Singapore, Rhode Island, Ohio, and North Carolina. The company has also supported science education, patient initiatives, and pandemic-relief programs through the Amgen Foundation. Its current pipeline includes oncology and immune therapies as well as MariTide, an investigational antibody-peptide candidate being studied for obesity and related metabolic disease. Amgen remains an independent, publicly traded biopharmaceutical group rather than a subsidiary of a larger pharmaceutical company.

History

Amgen was incorporated in April 1980 in Thousand Oaks, California, as Applied Molecular Genetics. Backed by venture capital and advised by scientists associated with leading American universities, the young company explored recombinant-DNA applications before concentrating on therapeutic proteins and biotechnology manufacturing. George Rathmann became its first chief executive officer later in 1980. Amgen went public on June 17, 1983, selling two million shares and raising nearly $40 million. The company adopted the Amgen name, derived from its original corporate identity. A major early breakthrough came when Fu-Kuen Lin’s team cloned the erythropoietin gene. The resulting recombinant product, Epogen, was approved by the U.S. Food and Drug Administration in 1989. Amgen also worked with Kirin Brewery on international rights and manufacturing arrangements. Research on granulocyte colony-stimulating factor led to Neupogen, approved in 1991 for reducing infection risk in patients receiving cancer chemotherapy. The company expanded its manufacturing base during the 1990s, including a major Puerto Rico facility, and received the United States National Medal of Technology and Innovation in 1994. Work on modified erythropoietin produced Aranesp, designed to remain active in the body longer. Gordon Binder led the company from 1988 until 2000, followed by Kevin Sharer. During this period Amgen broadened its commercial reach and developed major franchises in hematology, oncology, inflammation, and bone disease. In 2010 the FDA approved Prolia for osteoporosis and XGEVA for selected cancer-related skeletal complications. Amgen subsequently expanded its cardiovascular, immunology, and oncology portfolios through products such as Repatha, Otezla, Blincyto, Evenity, and Kyprolis. It also developed or acquired biosimilar capabilities. Robert Bradway became chief executive officer in 2012 and chairman in 2013. During the 2010s and early 2020s, Amgen supplemented internal discovery with acquisitions and collaborations. It acquired Five Prime Therapeutics, Rodeo Therapeutics, and ChemoCentryx, and entered partnerships involving immunology, protein degradation, RNA medicines, artificial intelligence, and manufacturing. Lumakras became the first approved targeted therapy for tumors carrying a KRAS G12C mutation after accelerated FDA approval in 2021. Tezspire, developed with AstraZeneca, added a severe-asthma therapy to the portfolio. Amgen acquired Horizon Therapeutics in 2023 for approximately $27.8 billion, strengthening rare-disease operations through Tepezza and Krystexxa. The company has continued expanding manufacturing in the United States and advancing oncology, respiratory, immune, and metabolic programs. MariTide, a long-acting investigational obesity treatment, became one of its most closely watched pipeline programs. Alongside commercial operations, the Amgen Foundation has supported science education, health equity, and relief efforts.

  • 2025

    MariTide enters Phase III development

    [6]

    Amgen began late-stage studies of MariTide for obesity and related metabolic conditions.

  • 2024

    IMDELLTRA launched

    [6]

    The FDA granted accelerated approval to IMDELLTRA for a form of small-cell lung cancer.

  • 2023

    Horizon acquisition completed

    [5]

    Amgen completed its acquisition of Horizon Therapeutics, expanding its rare-disease portfolio.

  • 2021

    Lumakras and Tezspire milestones

    [1]

    Lumakras received accelerated approval for KRAS G12C-mutated non-small-cell lung cancer, while Tezspire was approved for severe asthma later that year.

  • 2015

    Repatha approved

    [1]

    The FDA approved evolocumab, a PCSK9 inhibitor used to lower LDL cholesterol.

  • 2010

    Prolia and XGEVA approvals

    [1]

    The FDA approved denosumab products for osteoporosis and selected cancer-related bone complications.

  • 1991

    Neupogen approved

    [1]

    The FDA approved Neupogen to reduce infection risk associated with chemotherapy-induced immune suppression.

  • 1989

    Epogen approved

    [2]

    Epogen became the first recombinant human erythropoietin product approved in the United States.

  • 1983

    Initial public offering and Amgen name

    [2]

    The company completed its IPO and adopted the Amgen name, derived from Applied Molecular Genetics.

  • 1980

    Company founded

    [2]

    Applied Molecular Genetics was incorporated in Thousand Oaks, California, establishing the company that later became Amgen.

Products and positioning

A science-led biotechnology company focused on genetically informed, targeted therapies for serious diseases and areas of substantial unmet medical need, supported by proprietary research, biologics manufacturing, partnerships, and acquisitions.

  • Bone health · 2010

    Prolia

    A denosumab biologic used for certain patients with osteoporosis who face elevated fracture risk, particularly in postmenopausal osteoporosis and other specified settings.

  • Oncology and bone health · 2010

    XGEVA

    A denosumab product used to reduce skeletal complications associated with bone metastases and for selected giant-cell tumor of bone indications.

  • Cardiovascular disease · 2015

    Repatha

    Evolocumab is a PCSK9 inhibitor that lowers LDL cholesterol and is used for selected patients with hyperlipidemia and cardiovascular risk.

  • Immunology · 2014

    Otezla

    Apremilast is an oral phosphodiesterase-4 inhibitor used in conditions including psoriasis and psoriatic arthritis.

  • Hematologic oncology · 2014

    Blincyto

    Blinatumomab is a bispecific T-cell engager used in selected patients with B-cell precursor acute lymphoblastic leukemia.

  • Respiratory disease · 2021

    Tezspire

    Tezepelumab, developed with AstraZeneca, is a biologic used as an add-on maintenance treatment for certain patients with severe asthma.

  • Rare disease · 2020

    Tepezza

    Teprotumumab, obtained through the Horizon acquisition, is used to treat thyroid eye disease, also known as Graves’ ophthalmopathy.

  • Rare and metabolic disease · 2010

    Krystexxa

    Pegloticase is an enzyme replacement therapy for selected adults with chronic gout that has not responded adequately to conventional treatment.

  • Oncology · 2024

    IMDELLTRA

    Tarlatamab is a DLL3-directed bispecific T-cell engager approved through an accelerated pathway for certain adults with extensive-stage small-cell lung cancer.

  • Metabolic disease

    MariTide

    An investigational long-acting antibody-peptide candidate being studied for obesity and related metabolic disorders; it has not been established as an approved medicine.

Controversies

  • 2026

    France recalls Tavneos batches after deaths linked in Japan

    France's medicine safety agency ANSM said the recall of all Tavneos batches available in France would begin on August 19, after the drug, made by U.S. biotech firm Amgen and sold by partner companies worldwide, was linked to 20 deaths in Japan. The European Commission had revoked the drug's marketing authorisation earlier in the month.

  • 2024

    Amgen sues Colorado over drug price board

    Amgen filed a lawsuit against Colorado concerning actions by the state Prescription Drug Affordability Board regarding Enbrel. According to the reported filing, Amgen argued that the board's actions are unconstitutional. The company sought to overturn decisions about the drug and to strike down parts of the law establishing the board.

  • 2024

    Sandoz and Amgen settle US denosumab patent disputes

    Sandoz announced an agreement with Amgen resolving patent disputes concerning Sandoz's FDA-approved denosumab biosimilars. The agreement permits Sandoz to enter the US market with biosimilar versions of Prolia and Xgeva on May 31, 2025, or earlier under specified circumstances.

  • 2023

    FTC sues to block Amgen's acquisition of Horizon Therapeutics

    The U.S. Federal Trade Commission filed a lawsuit to stop Amgen's proposed $27.8 billion acquisition of Horizon Therapeutics. The FTC said it was concerned Amgen could use its leading drugs to pressure insurers and pharmacy benefit managers to grant favorable terms for Horizon products. Amgen said it was disappointed and disputed that the deal raised legitimate competitive issues.

  • 2023

    Amgen sues Novartis and Sandoz over proposed biosimilars

    Amgen filed a lawsuit against Novartis and its Sandoz business in federal court in New Jersey, alleging that Sandoz's proposed versions of Prolia and Xgeva infringe patents. Amgen requested that the court block the biosimilars until its patents expire. The dispute concerns proposed biosimilar products and patent protection for Prolia and Xgeva.

  • 2021

    Amgen files Supreme Court petition in patent dispute

    Amgen Inc. and its subsidiaries filed a petition for certiorari with the U.S. Supreme Court against Sanofi Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis US, LLC. The petition concerns the written-description requirement for patents and the level of detail that requirement demands.

  • 2012

    Off-label promotion, kickbacks, and pricing settlement

    Amgen pleaded guilty to a federal charge and paid $762 million to resolve criminal and civil allegations concerning promotion of medicines for unapproved uses, improper inducements, and false pricing submissions.

Read more

Brand decisions

  • 2023

    Amgen completes acquisition of Horizon TherapeuticsM&A

    Background

    Amgen announced that it completed its acquisition of Horizon Therapeutics for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion.

  • 2022

    Amgen agrees to acquire ChemoCentryxM&A

    Background

    Amgen announced an agreement to acquire ChemoCentryx in a cash transaction valued at approximately $3.7 billion, including the acquisition of ChemoCentryx's Tavneos treatment. The transaction was subject to customary closing conditions, stockholder approval and regulatory approvals, and was expected to close in the fourth quarter of 2022.

  • 2022

    Amgen announces acquisition of Horizon TherapeuticsM&A

    Background

    Amgen announced that it would acquire Horizon Therapeutics in a transaction valued at approximately $26.4 billion.

  • 2021

    Amgen completes acquisition of Five Prime TherapeuticsM&A

    Background

    Amgen completed its acquisition of Five Prime Therapeutics through a tender offer followed by a merger. Five Prime survived the merger, and its shares ceased trading on Nasdaq.

  • 2021

    Amgen announces $900 million acquisition of TeneobioM&A

    Background

    Amgen said it will pay $900 million for Teneobio, with the deal also including future contingent milestone payments of up to an additional $1.6 billion.

  • 2021

    Amgen completes acquisition of TeneobioM&A

    Background

    Amgen completed its previously announced acquisition of Teneobio in a deal worth up to $2.5 billion. The deal included Teneobio's antibody technologies and pipeline assets; three affiliates were spun off to Teneobio's current shareholders before completion.

  • 2020

    Amgen completes purchase of BeiGene equity stakeM&A

    Background

    Amgen completed its purchase of an approximately 20.5% equity stake in BeiGene for approximately $2.8 billion in cash.

  • 2019

    Amgen announces purchase of a 20.5% stake in BeiGeneM&A

    Background

    Amgen announced that it would purchase a 20.5% stake in BeiGene for approximately $2.7 billion in cash. The transaction had board approval and was expected to close in the first quarter of 2020, subject to stated conditions.

  • 2019

    Amgen completes acquisition of worldwide rights to OtezlaM&A

    Background

    Amgen announced that it completed its acquisition of worldwide rights to Otezla from Celgene Corporation. The acquisition was completed for $13.4 billion in cash, or approximately $11.2 billion net of anticipated future cash tax benefits.

Recent events

  • France recalls Tavneos batches after deaths linked in Japan[16]

    Reported

    France's medicine safety agency ANSM said the recall of all Tavneos batches available in France would begin on August 19, after the drug, made by U.S. biotech firm Amgen and sold by partner companies worldwide, was linked to 20 deaths in Japan. The European Commission had revoked the drug's marketing authorisation earlier in the month.

  • Sandoz and Amgen settle US denosumab patent disputes[23]

    Reported

    Sandoz announced an agreement with Amgen resolving patent disputes concerning Sandoz's FDA-approved denosumab biosimilars. The agreement permits Sandoz to enter the US market with biosimilar versions of Prolia and Xgeva on May 31, 2025, or earlier under specified circumstances.

  • Unconfirmed

    Amgen sues over state drug price cap[24]

    Reported

    Amgen sued the state over the Prescription Drug Affordability Board’s decision to cap the price of Enbrel. The report says Amgen believes the law permitting the cap is unconstitutional and conflicts with federal law.

  • Amgen sues Colorado over drug price board[22]

    Reported

    Amgen filed a lawsuit against Colorado over the state Prescription Drug Affordability Board’s actions concerning Enbrel, arguing that the board’s actions are unconstitutional and seeking to overturn decisions about the drug and strike down parts of the law establishing the board.

  • Amgen sues Colorado drug affordability board[25]

    Reported

    Amgen and two subsidiaries filed a lawsuit in U.S. District Court in Denver alleging that the Colorado law creating the Prescription Drug Affordability Board is unconstitutional and should be overturned. The suit challenges the board's finding that Enbrel is unaffordable.

  • FDA approves Amgen's WEZLANA[26]

    On October 31, the FDA approved Amgen's WEZLANA as a biosimilar to and interchangeable with Janssen's STELARA. The article identifies WEZLANA as the first product approved as a biosimilar to STELARA.

  • Amgen completes acquisition of Horizon Therapeutics[7]

    Reported

    Amgen announced that it completed its acquisition of Horizon Therapeutics for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion.

  • Generate:Biomedicines raises $273 million in Series C financing[27]

    Reported

    Generate:Biomedicines announced that it raised $273 million in Series C financing. The company said it would use the funds to advance its pipeline and validate and improve its AI platform.

  • FTC sues to block Amgen's acquisition of Horizon Therapeutics[18]

    Reported

    The U.S. Federal Trade Commission filed a lawsuit to stop Amgen's proposed $27.8 billion acquisition of Horizon Therapeutics. The FTC said it was concerned Amgen could use its leading drugs to pressure insurers and pharmacy benefit managers to grant favorable terms for Horizon products. Amgen said it was disappointed and disputed that the deal raised legitimate competitive issues.

  • Amgen sues Sandoz and Novartis over proposed biosimilars[20]

    Reported

    Amgen sued Novartis's Sandoz in New Jersey federal court, accusing Sandoz's proposed biosimilars of Prolia and Xgeva of infringing patents. Amgen asked the court to block the biosimilars until its patents expire; the allegations are not presented as a court determination.

Read more(49)

Sources77 sources

  1. 1Amgenen.wikipedia.org
  2. 2Amgen historyamgen.com
  3. 3Amgen leadership: Robert A. Bradwayamgen.com
  4. 4Department of Justice settlement announcementjustice.gov
  5. 5Amgen completes Horizon acquisitionamgen.com
  6. 6IMDELLTRA launchedamgen.com
  7. 7Amgen completes acquisition of Horizon Therapeuticsnews.cnyes.com
  8. 8Amgen agrees to acquire ChemoCentryxpmlive.com
  9. 9Amgen announces acquisition of Horizon Therapeuticsnews.cnyes.com
  10. 10Amgen completes acquisition of Five Prime Therapeuticsprnewswire.com
  11. 11Amgen announces $900 million acquisition of Teneobiosocaltech.com
  12. 12Amgen completes acquisition of Teneobiopharmaceutical-business-review.com
  13. 13Amgen completes purchase of BeiGene equity stakeprnasia.com
  14. 14Amgen announces purchase of a 20.5% stake in BeiGenefinance.sina.com.cn
  15. 15Amgen completes acquisition of worldwide rights to Otezlaprnewswire.com
  16. 16France recalls Tavneos batches after deaths linked in Japanthehindu.com
  17. 17Amgen files Supreme Court petition in patent disputelawstreetmedia.com
  18. 18FTC sues to block Amgen's acquisition of Horizon Therapeuticsrte.ie
  19. 19Amgen sues Novartis and Sandoz over proposed biosimilarsmedscape.com
  20. 20Amgen sues Novartis and Sandoz over proposed biosimilarsyahoo.com
  21. 21Amgen sues Novartis and Sandoz over proposed biosimilarslawstreetmedia.com
  22. 22Amgen sues Colorado over drug price boardcoloradosun.com
  23. 23Sandoz and Amgen settle US denosumab patent disputesfinancialpost.com
  24. 24Amgen就州药品价格上限提起诉讼bizwest.com
  25. 25安进起诉科罗拉多州药品可负担性委员会greeleytribune.com
  26. 26FDA批准Amgen的WEZLANAjdsupra.com
  27. 27Generate:Biomedicines 完成 2.73 亿美元 C 轮融资biospace.com
  28. 28安进泰国获得Great Place to Work认证en.prnasia.com
  29. 29Inversago Pharma完成C轮融资financialpost.com
  30. 30IDEAYA 与 Amgen 达成临床试验合作prnewswire.com
  31. 31FDA 批准 RIABNI 用于类风湿关节炎finanznachrichten.de
  32. 32Amgen named recipient of LUNGevity Hope Award for Corporate Leadershipprnewswire.com
  33. 33美国FDA批准Tezspire用于治疗重度哮喘prnewswire.com
  34. 34FDA批准Kyprolis联合治疗方案finanznachrichten.de
  35. 35FDA批准Kyprolis联合治疗方案用于多发性骨髓瘤healio.com
  36. 36Amgen宣布为BioLabs LA金票项目提供为期三年的赞助prnewswire.com
  37. 37EVOQ Therapeutics 与安进宣布许可与合作协议prnewswire.com
  38. 38FDA批准Amgen的RIABNIprnewswire.com
  39. 39安进终止与Cytokinetics的合作finanznachrichten.de
  40. 40NewAmsterdam Pharma从安进收购obicetrapib权益finanznachrichten.de
  41. 41FDA批准扩展KYPROLIS处方信息finanznachrichten.de
  42. 42FDA批准KYPROLIS联合治疗方案prnewswire.com
  43. 43安进、艾伯维和武田启动新冠治疗联合试验pacbiztimes.com
  44. 44百济神州宣布20.8亿美元股权融资finance.sina.com.cn
  45. 45安进与 Adaptive Biotechnologies 合作开发 COVID-19 治疗方案hospimedica.com
  46. 46安进与Adaptive宣布合作开发新冠中和抗体prnasia.com
  47. 47安进完成对百济神州的股权投资finance.sina.com.cn
  48. 48FDA 批准 Amgen 的 AVSOLAprnewswire.com
  49. 49安进将JSP191全球权利许可给Jasper Therapeuticsbenzinga.com
  50. 50安进上调 2019 年利润和营收预期euronews.com
  51. 51安进与百济神州同意在全球共同开发抗肿瘤药物finance.sina.com.cn
  52. 52安进同意购入百济神州20.5%股份finance.sina.com.cn
  53. 53安进公布2019年第三季度业绩prnewswire.com
  54. 54安进190亿元入股百济神州 药企联手淘金成大势所趋finance.sina.com.cn
  55. 55安进27亿美元收购百济神州20.5%股份 将创中外生物制药企业最大交易额finance.sina.com.cn
  56. 56安进斥资27亿美元入股百济神州,达成20余款肿瘤药物全球合作finance.sina.com.cn
  57. 57安进收购百济神州逾二成股份 开发安进抗肿瘤管线药finance.sina.com.cn
  58. 58安进以28亿美元完成收购百济神州约20.5%的股份finance.sina.com.cn
  59. 59百济神州宣布与安进公司建立全球肿瘤战略合作关系prnasia.com
  60. 60百济神州与安进达成全球战略合作,全球生物制药领域金额最大股权投资finance.sina.com.cn
  61. 61百济神州与美生物药巨头安进公司达成肿瘤战略合作finance.sina.com.cn
  62. 62中国市场的“诱惑” 安进入股百济神州finance.sina.com.cn
  63. 63中美药企最大金额"联姻":安进27亿美元入股百济神州finance.sina.com.cn
  64. 64Amgen Acquires Multispecific Immunotherapy Biotech Startup TeneoBio | JD Suprajdsupra.com
  65. 65AMGEN ANNOUNCES WEBCAST OF 2026 THIRD QUARTER FINANCIAL RESULTSprnewswire.com
  66. 66Amgen completes $27.8B acquisition of Horizon | Pacific Coast Business Timespacbiztimes.com
  67. 67Amgen Completes $27.8B Horizon Acquisition Following FTC Challengebiospace.com
  68. 68AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLCprnewswire.com
  69. 69Amgen Reports Fourth Quarter And Full Year 2019 Financial Resultsprnewswire.com
  70. 70AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTSprnewswire.com
  71. 71Amgen Reports Second Quarter 2020 Financial Resultsprnewswire.com
  72. 72BeiGene Announces Closing of Amgen Global Strategic Oncology Collaboration and Equity Investment - Amgenbenzinga.com
  73. 73BeiGene announces global strategic oncology collaboration with Amgenbiospectrumindia.com
  74. 74FDA approves Amgen’s rituximab biosimilar for treatment of moderate-to-severe RAhealio.com
  75. 75FDA Approves New KYPROLIS® (carfilzomib) Combination Regimen With DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and dexamethasone For Patients With Multiple Myeloma At First Or Subsequent Relapseprnewswire.com
  76. 76Horizon Therapeutics to be acquired in $28 billion deal, throwing future of Deerfield offices into questionchicagotribune.com
  77. 77US FTC sues to block Amgen's $27.8 billion deal for Horizon Therapeuticsyahoo.com

Cite this profile: Cite the canonical profile. /brandpedia/amgen · Editorial policy · How profiles are compiled